| Name | Title | Contact Details |
|---|
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 4,400 people across 40 countries.
Founded in 2007, Surgical Solutions, LLC is a national company headquartered in Chicago and Henderson, Kentucky (part of the Evansville, Indiana metropolitan area). The company specializes in providing non-clinical surgical services for minimally invasive (endoscopic and laparoscopic) surgical procedures to hospitals throughout the US.
Allurion Technologies manufactures the Elipse Balloon, the world`s first and only procedureless medical device for weight loss.
RMC Research Corp. is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Integrity Applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. Since its founding in 2001, Integrity Applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. Integrity Applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. After proof of concept in 2002, Integrity Applications developed the first working prototype, GlucoTrack in August 2003. GlucoTrack® Model DF-F received CE Mark approval in June 2013 and KFDA in March 2016. GlucoTrack is currently being marketed in the European Union and in South Korea.